[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Hamano A, Yamashita Y, Katoh Y, Yumura Y, Mikata K, Takase K, Ohgo Y, Noguchi S, Nagashima Y: [Two cases of retroperitoneal liposarcoma arisen from perirenal fat tissue, which could not be diagnosed preoperatively]. Hinyokika Kiyo; 2004 Dec;50(12):857-60
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of retroperitoneal liposarcoma arisen from perirenal fat tissue, which could not be diagnosed preoperatively].
  • We report two cases of retroperitoneal liposarcoma arisen from the perirenal fat tissue, which could not be diagnosed preoperatively.
  • Computed tomography and magnetic resonance image showed a mass over 10 cm that contained fat components in the retroperitoneal space.
  • The tumor was resected with left nephrectomy and histological examination revealed well differentiated liposarcoma.
  • As adjuvant therapy, he received chemotherapy and 30 months has passed uneventfully.
  • With clinical diagnosis as non-functioning adrenal tumor, he received left nephrectomy.
  • The pathological diagnosis was well differentiated liposarcoma, sclerosing type.
  • No adjuvant therapy was performed.
  • The characteristics of the images of the two cases were different despite the histological resemblance.
  • This difference was considered to be due to the difference in the distribution of lipomatous tissue in each patient.
  • [MeSH-major] Adipose Tissue / pathology. Kidney / pathology. Liposarcoma / diagnosis. Retroperitoneal Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Drug Administration Schedule. Epirubicin / administration & dosage. Humans. Magnetic Resonance Imaging. Male. Methotrexate / administration & dosage. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15682857.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate; MEC protocol 2
  •  go-up   go-down


2. Chen JH, Enloe BM, Weybright P, Campbell N, Dorfman D, Fletcher CD, Cory DG, Singer S: Biochemical correlates of thiazolidinedione-induced adipocyte differentiation by high-resolution magic angle spinning NMR spectroscopy. Magn Reson Med; 2002 Oct;48(4):602-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Thiazolidinediones, a class of synthetic ligands to the peroxisome proliferator-activated receptor-gamma, induce terminal adipocyte differentiation of 3T3 F442A cells, and have already been used as alternative therapeutic agents for the treatment of liposarcoma in clinical trials.
  • The biochemical changes occurring in the 3T3 F442A cell line and well-differentiated liposarcoma following induction of adipocyte differentiation with the thiazolidinedione troglitazone were measured using high-resolution magic angle spinning (MAS) nuclear magnetic resonance (NMR) spectroscopy.
  • The molar ratio of PTC to PC increased fourfold in differentiated 3T3 F442A cells compared to undifferentiated cells, suggesting a substantial increase in CTP:phosphocholine cytidylyltransferase activity with differentiation.
  • A 2.8-fold increase in the PTC:PC ratio was observed in the lipoma-like well-differentiated liposarcoma of three patients who were treated with troglitazone when compared to liposarcoma from patients not treated with this drug.
  • Thus, this ratio may be an NMR-detectable marker of troglitazone efficacy and response to differentiation therapy for liposarcoma.
  • [MeSH-major] Adipocytes / metabolism. Cell Differentiation / drug effects. Magnetic Resonance Spectroscopy / methods. Thiazoles / pharmacology. Thiazolidinediones
  • [MeSH-minor] 3T3 Cells. Animals. Antineoplastic Agents / therapeutic use. Cells, Cultured. Chromans / therapeutic use. Flow Cytometry. Humans. Ligands. Liposarcoma / drug therapy. Liposarcoma / metabolism. Mice. Phosphatidylcholines / metabolism. Phosphorylcholine / metabolism. Receptors, Cytoplasmic and Nuclear / metabolism. Transcription Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Wiley-Liss, Inc.
  • (PMID = 12353276.001).
  • [ISSN] 0740-3194
  • [Journal-full-title] Magnetic resonance in medicine
  • [ISO-abbreviation] Magn Reson Med
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA75720; United States / NCI NIH HHS / CA / R21-CA83759
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromans; 0 / Ligands; 0 / Phosphatidylcholines; 0 / Receptors, Cytoplasmic and Nuclear; 0 / Thiazoles; 0 / Thiazolidinediones; 0 / Transcription Factors; 107-73-3 / Phosphorylcholine; 2295-31-0 / 2,4-thiazolidinedione; I66ZZ0ZN0E / troglitazone
  •  go-up   go-down


3. Dubin MR, Chang EW: Liposarcoma of the tongue: case report and review of the literature. Head Face Med; 2006;2:21
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the tongue: case report and review of the literature.
  • BACKGROUND: Liposarcoma most commonly arises in the retroperitoneum and lower extremities.
  • Liposarcoma of the head and neck is rare, with only 12 previously reported cases of liposarcoma in the tongue.
  • CASE PRESENTATION: We present a case of well-differentiated liposarcoma of the tongue occurring in a 39 year old man, treated with surgical excision.
  • CONCLUSION: Liposarcoma of the head and neck is rare, and may easily be misdiagnosed clinically.
  • The diagnosis is made histologically.
  • Wide surgical excision is the treatment of choice, with limited data to support the use of radiation or chemotherapy.
  • Our case represents the longest follow-up period for a tongue liposarcoma, with 14 years disease-free following surgical extirpation.
  • [MeSH-major] Liposarcoma / diagnosis. Tongue Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Jan;89(1):66-72 [10630944.001]
  • [Cites] Oral Dis. 2004 Nov;10(6):398-400 [15533218.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001 Aug;92(2):194-201 [11505267.001]
  • [Cites] J Laryngol Otol. 2001 Oct;115(10):859-61 [11668010.001]
  • [Cites] Acta Otolaryngol. 2001 Sep;121(6):759-62 [11678177.001]
  • [Cites] Oral Oncol. 2002 Jan;38(1):117-9 [11755832.001]
  • [Cites] Mod Pathol. 2002 Oct;15(10):1020-31 [12379747.001]
  • [Cites] J Otolaryngol. 2002 Oct;31(5):327-8 [12512900.001]
  • [Cites] Am J Otolaryngol. 2003 Mar-Apr;24(2):121-7 [12649828.001]
  • [Cites] J Otolaryngol. 1976 Oct;5(5):410-4 [994279.001]
  • [Cites] Cancer. 1979 Feb;43(2):574-84 [421182.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):507-23 [534388.001]
  • [Cites] J Am Dent Assoc. 1984 Feb;108(2):231-2 [6584498.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1987 Mar;63(3):348-50 [3473362.001]
  • [Cites] Br J Oral Maxillofac Surg. 1992 Aug;30(4):268-9 [1510904.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Oct;118(10):1045-9 [1389054.001]
  • [Cites] J Oral Maxillofac Surg. 1994 Jun;52(6):595-8 [8189297.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1994 Oct;120(10):1151-5 [7917199.001]
  • [Cites] J Oral Pathol Med. 1995 Apr;24(4):180-4 [7783007.001]
  • [Cites] Arch Pathol Lab Med. 1996 Mar;120(3):292-5 [8629909.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1051-8 [8625207.001]
  • [Cites] J Oral Maxillofac Surg. 1998 Feb;56(2):224-7 [9461149.001]
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):452-6 [10349380.001]
  • [Cites] Surgery. 1954 Oct;36(4):687-712 [13195985.001]
  • [Cites] Cancer. 1960 Sep-Oct;13:932-50 [13696965.001]
  • [Cites] Virchows Arch Pathol Anat Physiol Klin Med. 1962;335:367-88 [13890373.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Jul;109(7):683-6 [10903052.001]
  • (PMID = 16872488.001).
  • [ISSN] 1746-160X
  • [Journal-full-title] Head & face medicine
  • [ISO-abbreviation] Head Face Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1553437
  • [General-notes] NLM/ Original DateCompleted: 20070720
  •  go-up   go-down


Advertisement
4. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


5. Lee TY, Folkman J, Javaherian K: HSPG-binding peptide corresponding to the exon 6a-encoded domain of VEGF inhibits tumor growth by blocking angiogenesis in murine model. PLoS One; 2010 Apr 01;5(4):e9945
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VEGF isoforms have different affinities for heparan sulphate proteoglycan (HSPG) as well as for VEGF receptors; HSPGs are important regulators in vascular development.
  • This 20 amino acids synthetic peptide prevents VEGF(165) binding to several different cell types, mouse embryonic sections and inhibits endothelial cell migration, despite its absence in VEGF(165) sequence.
  • Our in vivo anti-tumor studies show that the peptide inhibits tumor growth in both mouse Lewis-Lung Carcinoma and human Liposarcoma tumor-bearing animal models.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Sci. 2001 Mar;114(Pt 5):853-65 [11181169.001]
  • [Cites] Semin Cell Dev Biol. 2001 Apr;12(2):127-34 [11292378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11393-8 [12177445.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 19;1573(3):280-91 [12417410.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Glycoconj J. 2002 May-Jun;19(4-5):363-8 [12975617.001]
  • [Cites] Development. 2003 Dec;130(25):6245-55 [14602684.001]
  • [Cites] Development. 2004 Feb;131(3):601-11 [14729575.001]
  • [Cites] EMBO Rep. 2004 Mar;5(3):262-7 [14978510.001]
  • [Cites] Biochem Biophys Res Commun. 1991 Feb 28;175(1):68-76 [1998521.001]
  • [Cites] J Biol Chem. 1991 Jun 25;266(18):11947-54 [1711045.001]
  • [Cites] Mol Endocrinol. 1991 Dec;5(12):1806-14 [1791831.001]
  • [Cites] Science. 1992 Feb 21;255(5047):989-91 [1312256.001]
  • [Cites] J Cell Biol. 1992 Nov;119(3):493-501 [1400587.001]
  • [Cites] Biochem Biophys Res Commun. 1992 Sep 30;187(3):1579-86 [1417831.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):26031-7 [1464614.001]
  • [Cites] Mol Biol Cell. 1993 Dec;4(12):1317-26 [8167412.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26988-95 [7929439.001]
  • [Cites] J Biol Chem. 1995 Mar 24;270(12):6729-33 [7896817.001]
  • [Cites] J Biol Chem. 1995 May 12;270(19):11322-6 [7744769.001]
  • [Cites] J Cell Biol. 1995 May;129(4):895-8 [7538139.001]
  • [Cites] J Biol Chem. 1996 Mar 8;271(10):5638-46 [8621427.001]
  • [Cites] Cancer Metastasis Rev. 1996 Jun;15(2):153-8 [8842486.001]
  • [Cites] J Biol Chem. 1997 Mar 14;272(11):7151-8 [9054410.001]
  • [Cites] Int J Biochem Cell Biol. 1997 May;29(5):709-14 [9251237.001]
  • [Cites] Cancer Res. 1998 May 1;58(9):1952-9 [9581838.001]
  • [Cites] J Biol Chem. 1998 Sep 25;273(39):24979-82 [9737951.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Nature. 1999 Jul 15;400(6741):281-4 [10421372.001]
  • [Cites] Nat Rev Mol Cell Biol. 2005 Jul;6(7):530-41 [16072037.001]
  • [Cites] Exp Cell Res. 2005 Sep 10;309(1):24-31 [15996656.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] J Biol Chem. 2006 Jan 20;281(3):1731-40 [16258170.001]
  • (PMID = 20376344.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA045548; United States / NCI NIH HHS / CA / R01 CA064481; United States / NCI NIH HHS / CA / P01-CA45548; United States / NCI NIH HHS / CA / R01-CA064481
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Heparan Sulfate Proteoglycans; 0 / Peptides; 0 / Vascular Endothelial Growth Factor A
  • [Other-IDs] NLM/ PMC2848586
  •  go-up   go-down


6. Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O: Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21. Oncogene; 2002 Mar 28;21(14):2261-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gains of 1q21-q23 have been associated with metastasis and chemotherapy response, particularly in bladder cancer, hepatocellular carcinomas and sarcomas.
  • COAS2 was overexpressed almost exclusively in aggressive metastatic or chemotherapy resistant tumours.
  • Although COAS2 was generally more amplified than COAS1, it was not expressed in well-differentiated liposarcomas, where amplification of this region is very common.
  • Quite likely, the different genes may give selective advantages to different subsets of tumours.

  • COS Scholar Universe. author profiles.
  • SciCrunch. HGNC: Data: Gene Annotation .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11948409.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB033071/ AF345651/ AL117237/ BG154169
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm; EC 5.2.1.- / Cyclophilins
  •  go-up   go-down


7. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O: Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A. Int J Cancer; 2007 Jul 1;121(1):199-205
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A.
  • However, Nutlin-based therapy could be even more important in more common sarcoma types where this aberration is frequent.
  • The well- and de-differentiated liposarcomas have complex marker chromosomes, consistently including multiple copies of the MDM2 locus.
  • Since amplification seems to be a primary aberration in these tumors, whereas amplification in osteosarcoma generally is a progression marker, the underlying biological mechanisms may be different.
  • We have therefore investigated the molecular response to Nutlin treatment in several liposarcoma cell lines with such markers, as well as a panel of other sarcoma cell lines.
  • We report that Nutlin efficiently stabilized p53 and induced downstream p53 dependent transcription and apoptosis in liposarcoma cells with amplified MDM2 in vitro.
  • Thus, Nutlin represents a promising new therapeutic principle for the treatment of an increasing group of sarcomas.
  • [MeSH-major] Imidazoles / pharmacology. Liposarcoma / drug therapy. Liposarcoma / pathology. Piperazines / pharmacology. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Proto-Oncogene Proteins c-mdm2 / metabolism
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Genotype. Humans. Sensitivity and Specificity. Signal Transduction. Tumor Suppressor Protein p53 / metabolism


8. Jones RL, Fisher C, Al-Muderis O, Judson IR: Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer; 2005 Dec;41(18):2853-60
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of liposarcoma subtypes to chemotherapy.
  • Liposarcoma is one of the most common soft tissue sarcomas and has a number of different subtypes: well-differentiated; dedifferentiated; myxoid/round cell; and pleomorphic.
  • However, the response of these subgroups to chemotherapy is not well documented.
  • In this study, we have conducted a retrospective analysis of a prospectively maintained database of soft tissue sarcoma patients treated at the Royal Marsden Hospital.
  • Eighty-eight liposarcoma patients who received chemotherapy between August 1989 and June 2004 were identified.
  • The response rates to chemotherapy of the different histological subtypes and overall and progression free survival were investigated.
  • A statistically significant higher response rate to first-line chemotherapy was observed in patients with myxoid liposarcoma compared to de- and well-differentiated tumours, 48% (95%CI; 28-69) and 11% (95%CI; 2-29), P = 0.005.
  • Similarly, those with myxoid liposarcoma had a significantly higher response rate compared to all other liposarcoma patients, 48% (95%CI; 28-69) and 18% (95%CI; 8-31).
  • This retrospective analysis suggests that myxoid liposarcoma is relatively chemosensitive in comparison to a combination of other liposarcomas, and in particular de- and well-differentiated tumours.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Liposarcoma, Myxoid / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Prospective Studies. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289617.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Calleja Subirán MC, Hernández Gutiérrez FJ, López Elzaurdia C, Revestido García R: [Liposarcoma histologic subtypes: four cases reports]. An Med Interna; 2007 Apr;24(4):179-84
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma histologic subtypes: four cases reports].
  • [Transliterated title] Subtipos histológicos de liposarcoma: presentación de cuatro casos.
  • The liposarcoma is a malignant tumor of mesodermic origin derived of the adipose tissue.
  • Liposarcoma s types, according to his histological diagnosis, are: mixoide, pleomorphic, well differentiated and dedifferentiated.
  • His treatment is the radical surgery, it is possible, together with radiation therapy and/or chemotherapy.
  • Four patients diagnosed of liposarcoma are shown up, a case of liposarcoma well differentiated, another case of liposarcoma pleomorphic and two cases about liposarcoma mixoide; with the characteristic that one of these two cases presented a local recidivation with a dediferenciation of itself.
  • The evolution of the four cases, was in a different way.
  • [MeSH-major] Abdominal Neoplasms / pathology. Liposarcoma / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Abdomen / pathology. Aged. Diagnosis, Differential. Female. Humans. Liposarcoma, Myxoid / diagnosis. Liposarcoma, Myxoid / pathology. Liposarcoma, Myxoid / radiography. Liposarcoma, Myxoid / surgery. Male. Middle Aged. Prognosis. Radiography, Abdominal. Retroperitoneal Space / pathology. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867902.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Gupta R, Sharma A, Arora R, Kulkarni MP, Chattopadhaya TK, Singh MK: Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist. J Gastrointest Cancer; 2010 Mar;41(1):79-83
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Well-differentiated mesenteric liposarcoma with osseous metaplasia: a potential diagnostic dilemma for the pathologist.
  • BACKGROUND: Mesenteric liposarcoma is a rare intra-abdominal sarcoma with very few cases reported in the available English literature.
  • Dedifferentiation in liposarcoma manifests as a nonlipogenic sarcoma, which is usually high-grade and may show osteosarcomatous differentiation rarely.
  • To the best of our knowledge, osteoid metaplasia in a well-differentiated liposarcoma without evidence of dedifferentiation has not been documented in the available literature.
  • CASE: We describe the case of a middle-aged adult man with a well-differentiated liposarcoma of the mesentery.
  • The patient presented with a recurrent tumor 5 years after the initial surgery.
  • At recurrence, the histological features were those of a well-differentiated liposarcoma with focal osseous metaplasia without any evidence of dedifferentiation in the extensive sections examined.
  • CONCLUSION: Osseous metaplasia is a rare phenomenon in lipomas and dedifferentiated liposarcomas.
  • Such an occurrence in a recurrent well-differentiated liposarcoma is a perplexing problem due to the potential confusion with dedifferentiation.
  • This needs to be recognized to avoid overzealous chemotherapy and/or radiotherapy, which is required for dedifferentiated tumors.
  • [MeSH-major] Calcinosis / pathology. Liposarcoma / pathology. Mesentery / pathology. Neoplasm Recurrence, Local / pathology. Peritoneal Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Metaplasia. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Intern Med. 2007;46(7):373-5 [17409600.001]
  • [Cites] Am J Surg Pathol. 1994 Nov;18(11):1150-7 [7943536.001]
  • [Cites] World J Gastroenterol. 2007 Aug 14;13(30):4147-8 [17696239.001]
  • [Cites] Skeletal Radiol. 2003 May;32(5):286-9 [12679843.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):669-75 [16003776.001]
  • [Cites] Clin Neuropathol. 1996 Jan-Feb;15(1):60-2 [8998859.001]
  • [Cites] Jpn J Clin Oncol. 2006 Nov;36(11):735-8 [17000700.001]
  • [Cites] Semin Diagn Pathol. 2001 Nov;18(4):258-62 [11757865.001]
  • [Cites] AJR Am J Roentgenol. 1996 Apr;166(4):829-33 [8610559.001]
  • [Cites] Intern Med. 1998 Oct;37(10):884-90 [9840715.001]
  • [Cites] Surg Today. 1994;24(11):1003-6 [7772897.001]
  • (PMID = 20058101.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Ylagan LR, Bhalla S: Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up. Acta Cytol; 2001 Jul-Aug;45(4):641-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration cytology of a dedifferentiated liposarcoma: report of a case with histologic and immunohistochemical follow-up.
  • It occurs in tumors of the retroperitoneum and in those undergoing treatment.
  • This usually occurs in the setting of radiation or chemotherapy or as a spontaneous process over a long period.
  • CASE: We report the cytologic features of a dedifferentiated liposarcoma arising in a 76-year-old man who had a history of well-differentiated liposarcoma.
  • There were multinucleated, pleomorphic giant cells with abundant cytoplasm, smaller clusters of cells with a high nuclear/cytoplasmic ratio and cells with spindled and elongated nuclear features.
  • The follow-up surgical resection specimen showed a dedifferentiated liposarcoma with strong and diffuse immunoreactivity to vimentin, desmin and CD68 in the large, pleomorphic cells; focal and weak immunoreactivity to smooth muscle actin and S-100 in these cells; and strong and focal immunoreactivity to desmin, smooth muscle actin and muscle-specific actin in the spindle cells.
  • CONCLUSION: Dedifferentiation of a well-differentiated liposarcoma should be entertained in the setting of a mass lesion in the retroperitoneum in patients with prior histories of well-differentiated liposarcoma.
  • [MeSH-major] Biopsy, Needle. Liposarcoma / pathology. Pelvic Neoplasms / pathology. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunohistochemistry. Male. Pelvis / radiography. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11480734.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Yokoi M, Hosokawa K, Funaki H, Yoshitani S, Kinami S, Omote K, Ueda N, Nakano Y, Kosaka T, Minato H: [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2114-6
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal dedifferentiated liposarcoma successfully treated with IFM and CDDP].
  • The patient was diagnosed with retroperitoneal liposarcoma.
  • On histopathology, the dark red lesions showed dedifferentiated liposarcoma, and the yellowish lesions showed well-differentiated liposarcoma.
  • Despite VAC chemotherapy (VCR 1.5 mg, ACD 0.5 mg, CPA 900 mg), progressive disease (PD) was noted.
  • As second-line chemotherapy, weekly IFM (2 g)+CDDP (30 mg) was given.
  • This case suggests that IFM+CDDP may be useful in dedifferentiated liposarcoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liposarcoma / drug therapy. Retroperitoneal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Liposarcoma.
  • Genetic Alliance. consumer health - Retroperitoneal liposarcoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037341.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


13. Yamamoto T, Marui T, Akisue T, Hitora T, Kawamoto T, Nagira K, Nakatani T, Yoshiya S, Kurosaka M: Management of liposarcoma occurring in pregnant women. Anticancer Res; 2003 Jan-Feb;23(1B):799-802
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of liposarcoma occurring in pregnant women.
  • BACKGROUND: The coexistence of pregnancy and liposarcoma is rare.
  • Only 12 cases of pregnancy-associated liposarcoma have previously been reported in the English-language literature.
  • MATERIALS AND METHODS: We present two cases of liposarcoma occurring in pregnant patients: one myxoid liposarcoma in a 29-year-old woman at 29 weeks' gestation; another well-differentiated liposarcoma in a 44-year-old woman at 22 weeks' gestation.
  • The patient was subsequently treated with chemotherapy and radiotherapy.
  • The second patient awaited delivery until 32 weeks' gestation with no treatment of the tumor because she had a low-grade sarcoma.
  • After cesarean section, surgical treatment followed.
  • CONCLUSION: Treatment of sarcomas occurring during pregnancy is difficult.
  • Both mother and fetus should be appropriately managed, depending on the trimester at the time of diagnosis and the histological type and grade of the tumor.
  • [MeSH-major] Liposarcoma / therapy. Pregnancy Complications, Neoplastic / therapy
  • [MeSH-minor] Adult. Cesarean Section. Combined Modality Therapy. Extremities. Female. Humans. Pregnancy. Pregnancy Outcome

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12680186.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


14. Buyukhatipoglu H, Sevinc A, Camci C, Buyukberber S, Sari I: A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation. Clin Lab Haematol; 2006 Oct;28(5):343-6
MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case representing coexistence of acute myeloblastic leukemia and dedifferentiated liposarcoma: the possible role of chemotherapy in triggering dedifferentiation.
  • Dedifferentiated and well-differentiated liposarcomas are the two pathological subtypes of liposarcoma, based on the WHO classification.
  • Transition from well-differentiated to dedifferentiated liposarcoma is a well-recognized phenomenon.
  • Well-differentiated tumors are known to have low malignancy grade.
  • This process largely is believed to progress in a time-dependant manner; however, time is not the only factor of importance.
  • To date, the coexistence of AML and liposarcoma has not been reported in the literature.
  • In this paper, we report on a case of coexistence of AML and liposarcoma, and on the unusual behavior of a well-differentiated tumor after dedifferentiation occurs.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Leukemia, Myeloid, Acute / drug therapy. Liposarcoma / chemically induced

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16999727.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


15. Kasper B, Ouali M, Van Glabbeke M, Blay J, Bramwell VH, Woll PJ, Schöffski P: Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials. J Clin Oncol; 2009 May 20;27(15_suppl):10573

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in adolescents and young adults (AYA) with high-risk soft tissue sarcoma (STS) treated by adjuvant chemotherapy: A study based on two pooled European Organisation for Research and Treatment of Cancer (EORTC) clinical trials.
  • : 10573 Background: We conducted a retrospective study pooling data from two clinical trials in high risk STS patients with the objective to compare two different age groups: 15 - 29 years (AYA population) and ≥ 30 years.
  • METHODS: Patients selected for analysis were treated in two randomized trials of adjuvant chemotherapy in STS (EORTC 62771 and 62931).
  • A total of 793 patients were included with a median follow-up (FU) of 8.74 years (AYA population: n = 161, median FU 9.46 years; patients ≥ 30 years: n = 632, median FU 8.62 years).
  • The variables of the multivariate analysis were gender, subtype and grade, tumor size and localization (limb vs. other), absence or presence of local recurrence and treatment (control arm vs. adjuvant chemotherapy).
  • The commonest sarcoma subtype in the AYA population was synovial sarcoma (29 %), whereas leiomyosarcoma (18 %), malignant fibrous histiocytoma (MFH, 16 %) and liposarcoma (15 %) were more frequent in patients ≥ 30 years.
  • For OS, independent favorable prognostic factors were low grade and small tumor size for both groups; radical resection and MFH or liposarcoma subtype were factors of favorable prognosis for patients ≥ 30 years only.
  • For RFS, favorable prognostic factors were small tumor size and low grade for both groups; tumor location in the extremities was a factor of favorable prognosis for the AYA population only, whereas radical resection and adjuvant chemotherapy treatment were favorable factors for patients ≥ 30 years only.
  • Interestingly, adjuvant chemotherapy was associated with improved RFS only in patients ≥ 30 years.
  • The results may have further implications on the treatment of STS patients in different age groups as well as the design of future clinical trials.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963782.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Kostka R, Baitler T, Zachoval R, Sosna B, Palascak P: [Liposarcoma of the spermatic cord]. Prog Urol; 2006 Apr;16(2):215-7
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the spermatic cord].
  • Liposarcoma of the spermatic cord is rare.
  • Value of adjuvant radiotherapy/chemotherapy remains uncertain.
  • We report on a 62 year old male who presented with a half a year history of a soft painless mass in the left scrotum extending from the groin up to the testis.
  • Histological examination revealed a well-differentiated liposarcoma of sclerosing subtype.
  • No evidence of recurrence or metastases has been noted during the 6-month and one year follow-up without any postoperative adjuvant therapy.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16734250.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


17. May M, Seehafer M, Helke C, Gunia S, Hoschke B: [Liposarcoma of the spermatic cord--report of one new case and review of the literature]. Aktuelle Urol; 2004 Apr;35(2):130-3
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Liposarcoma of the spermatic cord--report of one new case and review of the literature].
  • [Transliterated title] Liposarkom des Samenstrangs--Darstellung eines Falls.
  • Liposarcoma of the spermatic cord is a rare entity.
  • Although most liposarcomas of the spermatic cord are well-differentiated, the propensity for local recurrence is high.
  • Preferential treatment of spermatic cord liposarcoma is radical orchiectomy with high ligation of the cord.
  • Radiation therapy is recommended in addition to surgery in cases with evidence of more aggressive tumour behavior (i.e., high-grade tumour, lymphatic invasion, inadequate margin, or recurrence).
  • A 39-year-old-male presented with a 4-year history of a mass in the left scrotum.
  • Pathological analysis demonstrated a well-differentiated liposarcoma with tumour detection in the surgical margin.
  • Without any postoperative adjuvant therapy in evidence of recurrence or metastasis was noted during the 12-month follow-up period.
  • Paratesticular liposarcomas are most commonly well-differentiated and lipoma-like and have a prolonged clinical course.
  • Radical orchiectomy with wide local excision of the mass is the recommended therapy, while adjuvant radiotherapy may be considered in high-grade tumours and in recurrent liposarcomas.
  • Retroperitoneal lymphadenectomy does not offer any additional therapeutic benefit, and the role of chemotherapy is not well defined.
  • Regardless of initial therapy, the risk of local recurrence always necessitates long-term followup.
  • [MeSH-major] Genital Neoplasms, Male. Liposarcoma. Spermatic Cord
  • [MeSH-minor] Adult. Diagnosis, Differential. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Orchiectomy. Radiotherapy, Adjuvant. Reoperation. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15146377.001).
  • [ISSN] 0001-7868
  • [Journal-full-title] Aktuelle Urologie
  • [ISO-abbreviation] Aktuelle Urol
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


18. Okby NT, Travis WD: Liposarcoma of the pleural cavity: clinical and pathologic features of 4 cases with a review of the literature. Arch Pathol Lab Med; 2000 May;124(5):699-703
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposarcoma of the pleural cavity: clinical and pathologic features of 4 cases with a review of the literature.
  • BACKGROUND: Primary liposarcomas of the pleura are extremely rare malignancies, and relatively few reports appear in the world literature.
  • DESIGN: We compiled a small series of 4 cases of primary pleural liposarcoma from the files of the Armed Forces Institute of Pathology (Washington, DC) and compared the histopathologic and clinical features of these 4 cases with those of 9 previously published cases.
  • Histologic subtypes in the 9 cases with available information included 5 myxoid liposarcomas, 1 well-differentiated liposarcoma, and 3 liposarcomas with mixtures of histologic types.
  • Surgical resection with or without chemotherapy appeared to be the most common form of treatment, although radiation therapy was used in some cases and seemed beneficial.
  • Survival information was available for 11 cases; 4 patients died of disease at 7, 9, 12, and 19 months; 1 died of heart failure 2 days after presentation; 1 died of unknown causes 16 months after presentation; and 3 patients were alive without tumor at 5, 16, and 66 months after diagnosis.
  • CONCLUSIONS: Primary pleural liposarcomas occur predominantly in older men, and the myxoid histologic subtype is the most common.
  • Radiographic or surgical evaluation is important to distinguish primary pleural liposarcoma from chest wall or mediastinal sarcomas, as well as metastases from other sites.
  • Although further investigation is needed, evidence from the cases reviewed here indicates that surgical resection with adjuvant radiation therapy may benefit patients with primary pleural liposarcoma.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma, Myxoid / pathology. Pleura / pathology. Pleural Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10782150.001).
  • [ISSN] 0003-9985
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 15
  •  go-up   go-down


19. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol; 2009 Sep 1;27(25):4188-96
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules.
  • PURPOSE: To evaluate the safety and efficacy of trabectedin in a phase II, open-label, multicenter, randomized study in adult patients with unresectable/metastatic liposarcoma or leiomyosarcoma after failure of prior conventional chemotherapy including anthracyclines and ifosfamide.
  • Time to progression (TTP) was the primary efficacy end point, based on confirmed independent review of images.
  • Although somewhat more neutropenia, elevations in AST/ALT, emesis, and fatigue occurred in the q3 weeks 24-hour, this regimen was reasonably well tolerated.
  • CONCLUSION: Prior studies showed clinical benefit with trabectedin in patients with sarcomas after failure of standard chemotherapy.
  • This trial documents superior disease control with the q3 weeks 24-hour trabectedin regimen in liposarcomas and leiomyosarcomas, although the qwk 3-hour regimen also demonstrated activity relative to historical comparisons.
  • Trabectedin may now be considered an important new option to control advanced sarcomas in patients after failure of available standard-of-care therapies.
  • [MeSH-major] Anthracyclines / therapeutic use. Antibiotics, Antineoplastic / therapeutic use. Antineoplastic Agents, Alkylating / administration & dosage. Antineoplastic Agents, Alkylating / therapeutic use. Dioxoles / administration & dosage. Drug Resistance, Neoplasm. Ifosfamide / therapeutic use. Leiomyosarcoma / drug therapy. Liposarcoma / drug therapy. Tetrahydroisoquinolines / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Australia. Disease-Free Survival. Drug Administration Schedule. Europe. Female. Humans. Infusions, Intravenous. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. North America. Proportional Hazards Models. Risk Assessment. Time Factors. Treatment Failure. Young Adult


20. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The approach to the management of retroperitoneal tumors begins with a complete history and physical examination.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


21. Lahat G, Anaya DA, Wang X, Tuvin D, Lev D, Pollock RE: Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches. Ann Surg Oncol; 2008 Jun;15(6):1585-93
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resectable well-differentiated versus dedifferentiated liposarcomas: two different diseases possibly requiring different treatment approaches.
  • BACKGROUND: Division of retroperitoneal liposarcoma (RPLS) into well-differentiated (WD) and dedifferentiated (DD) subtypes is established; however, WD and DD are usually treated similarly.
  • We hypothesized that WD and DD have distinct biological behaviors mandating different treatments.
  • A significant proportion of DD (37.7%) received chemotherapy compared to WD (1.7%; p < 0.0001).
  • Median time to recurrence was 55.5 months in WD versus 13.5 months in DD (p < 0.0001).
  • Treatment should therefore reflect these biologic differences by maximizing survivorship while avoiding unnecessarily extensive multivisceral resection.
  • SYNOPSIS: The biological behaviors of well-differentiated and dedifferentiated liposarcomas differ significantly.
  • This article presents outcomes of two different surgical approaches that were implemented at the UTMDACC, treating these tumors as different disease entities.
  • [MeSH-major] Liposarcoma / pathology. Liposarcoma / surgery. Retroperitoneal Neoplasms / pathology. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg Oncol. 2008 Jun;15(6):1555-6 [18347875.001]
  • (PMID = 18398663.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


22. Miettinen M: From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol; 2006;587:99-113
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] From morphological to molecular diagnosis of soft tissue tumors.
  • Cytogenetic discoveries of balanced translocations in soft tissue tumors have opened the way to molecular genetic definition of these translocations as gene fusions from the late 1980s.
  • Many sarcomas are known to have such fusions, and the demonstration of the fusion transcripts in tumor tissue is of great value in specific diagnosis of synovial sarcoma (SYT-SSX), Ewing sarcoma (EWS-Fli1), clear cell sarcoma (EWS-ATF1), myxoid liposarcoma (FUS-CHOP), and other sarcomas.
  • Demonstration of SYT-SSX and EWS-ATF1 fusion assists in the diagnosis of synovial and clear cell sarcomas in unusual locations, such as the gastrointestinal tract, where these tumors occur with low frequency.
  • Demonstration of sarcoma translocations and their fusion by different assays is well established; use of in situ hybridization is limited by availability of specific probes.
  • Activating mutations in two related receptor tyrosine kinases (RTKs), KIT, and platelet-derived growth factor receptor alpha (PDGFRA) is central to the pathogenesis of gastrointestinal stromal tumors (GISTs), and countering the mutational activation by specific tyrosine kinase inhibitors, such as Imatinib mesylate, is now standard treatment for metastatic GISTs.
  • Mutation type influences therapy responsiveness, but fortunately very few GISTs carry primarily Imatinib-resistant mutations.
  • Secondary drug resistance acquired during Imatinib treatment based on new, Imatinib-resistant mutations is a major problem limiting treatment success.
  • Schwannoma types may differ in their pathogenesis: gastrointestinal schwannomas lack NF2 changes suggesting a different pathogenesis.
  • [MeSH-major] Genetic Testing. Soft Tissue Neoplasms / genetics. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Genetic Testing.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17163160.001).
  • [ISSN] 0065-2598
  • [Journal-full-title] Advances in experimental medicine and biology
  • [ISO-abbreviation] Adv. Exp. Med. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 70
  •  go-up   go-down


23. Bradley JC, Caplan R: Giant retroperitoneal sarcoma: a case report and review of the management of retroperitoneal sarcomas. Am Surg; 2002 Jan;68(1):52-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent resection of a well-differentiated liposarcoma arising from his retroperitoneum measuring 50 cm and weighing 11.7 kg (25.8 lb).
  • This is the second largest retroperitoneal soft-tissue sarcoma (RSTS) that has been reported.
  • Over the last 15 years 1123 patients with RSTS in 25 series have been reported with a mean tumor size of 15.7 cm.
  • Diagnosis and treatment of RSTS can be extremely challenging for a general surgeon.
  • Treatment of RSTS remains surgical.
  • Multiple trials of chemotherapy and radiation therapy show no survival benefit.
  • The only successful treatment of this tumor is complete excision; 51.4 per cent of tumors can be completely excised, and 50.2 per cent of these excisions include adjacent organs.
  • With aggressive surgical therapy survival is increased to 58.0 and 39.6 per cent.
  • [MeSH-major] Liposarcoma / surgery. Retroperitoneal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12467318.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


24. Benaragama KS, Neequaye SK, Maudgil D, Gordon AG: Small bowel liposarcoma--a rare cause of small bowel perforation. BMJ Case Rep; 2010;2010
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small bowel liposarcoma--a rare cause of small bowel perforation.
  • The histology demonstrated a well-differentiated liposarcoma.
  • Liposarcomas are the most common soft tissue sarcomas in adults but occurrence in the gastrointestinal tract is extremely rare.
  • Surgical resection with clear margins is the treatment of choice for primary liposarcomas.
  • They are moderately radiosensitive and chemotherapy is non-effective.
  • Although gastrointestinal liposarcomas have been previously reported, this is the first reported case of a primary liposarcoma associated with a small bowel perforation.
  • [MeSH-major] Ileal Neoplasms / diagnosis. Intestinal Perforation / etiology. Liposarcoma / diagnosis
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Ileal Diseases / diagnosis. Ileal Diseases / etiology. Male

  • Genetic Alliance. consumer health - Liposarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 1972 Aug;58(2):172-6 [5056514.001]
  • [Cites] Ann Surg. 1974 Aug;180(2):175-9 [4843046.001]
  • [Cites] Acta Pathol Microbiol Scand Suppl. 1975;(253):1-71 [1059326.001]
  • [Cites] Am J Gastroenterol. 1988 Jan;83(1):89-92 [3337069.001]
  • [Cites] Tumori. 1993 Apr 30;79(2):77-91 [8346570.001]
  • [Cites] AJR Am J Roentgenol. 1995 Jan;164(1):129-34 [7998525.001]
  • [Cites] Ann Surg Oncol. 1999 Jun;6(4):389-94 [10379861.001]
  • [Cites] Int Surg. 1999 Apr-Jun;84(2):163-7 [10408290.001]
  • (PMID = 22791735.001).
  • [ISSN] 1757-790X
  • [Journal-full-title] BMJ case reports
  • [ISO-abbreviation] BMJ Case Rep
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3029041
  •  go-up   go-down


25. Rossi S, Canal F, Licci S, Zanatta L, Laurino L, Gottardi M, Gherlinzoni F, Dei Tos AP: Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy. Hum Pathol; 2009 Jul;40(7):1040-4
MedlinePlus Health Information. consumer health - Myelodysplastic Syndromes.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic evidence of metastatic myxoid liposarcoma and therapy-related myelodysplastic syndrome in a bone marrow biopsy.
  • Myxoid liposarcoma exhibits a peculiar clinical behavior, with a tendency to spread to serosal membranes, distant soft tissues, and bones, even in the absence of lung metastases.
  • Therapy-related hematological neoplasms are well-known side effects of cytotoxic chemotherapy.
  • We describe an exceptional case of metastatic myxoid liposarcoma of the spine associated with therapy-related refractory anemia with excess of blasts in a 37-year-old woman who underwent multi-agent chemotherapy for a myxoid liposarcoma of the left thigh.
  • Cytogenetic analyses of bone marrow aspirate disclosed the presence of 2 different rearrangements, subsequently confirmed by fluorescent in situ hybridization and was crucial in making the correct diagnosis.
  • [MeSH-major] Liposarcoma, Myxoid / pathology. Myelodysplastic Syndromes / pathology. Neoplasms, Second Primary / pathology
  • [MeSH-minor] Adult. Anemia, Refractory / pathology. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bone Marrow Cells / pathology. Chromosomes, Human, Pair 11. Combined Modality Therapy / adverse effects. Female. Humans. Leukemia, Myeloid, Acute / pathology. Soft Tissue Neoplasms / pathology. Thigh / pathology


26. Chibon F, Mariani O, Derré J, Mairal A, Coindre JM, Guillou L, Sastre X, Pédeutour F, Aurias A: ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications. Genes Chromosomes Cancer; 2004 May;40(1):32-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASK1 (MAP3K5) as a potential therapeutic target in malignant fibrous histiocytomas with 12q14-q15 and 6q23 amplifications.
  • This genetic finding, very similar to that in well-differentiated liposarcomas, strongly suggests that these tumors actually correspond to undifferentiated liposarcomas.
  • Treatment of a cell line with specific inhibitors of ASK1 protein resulted in the bypass of the differentiation block and induction of a strong adipocytic differentiation.
  • These observations indicate that ASK1 is a target for new therapeutic management of these aggressive tumors.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Chromosomes, Human, Pair 12 / genetics. Chromosomes, Human, Pair 6 / genetics. Gene Amplification / genetics. Histiocytoma, Benign Fibrous / drug therapy. MAP Kinase Kinase Kinases / antagonists & inhibitors. MAP Kinase Kinase Kinases / physiology. Retroperitoneal Neoplasms / drug therapy
  • [MeSH-minor] Adipocytes / drug effects. Adipocytes / pathology. Aged. Cell Differentiation / drug effects. Cell Differentiation / genetics. Cell Line, Tumor. Enzyme Inhibitors / pharmacology. Female. Humans. Liposarcoma / drug therapy. Liposarcoma / enzymology. Liposarcoma / genetics. MAP Kinase Kinase Kinase 5. MAP Kinase Signaling System / drug effects. MAP Kinase Signaling System / genetics. Male. Middle Aged. Nucleic Acid Hybridization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Wiley-Liss, Inc.
  • (PMID = 15034865.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Enzyme Inhibitors; EC 2.7.11.25 / MAP Kinase Kinase Kinase 5; EC 2.7.11.25 / MAP Kinase Kinase Kinases; EC 2.7.11.25 / MAP3K5 protein, human
  •  go-up   go-down


27. Skubitz KM, Pambuccian S, Manivel JC, Skubitz AP: Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors. J Transl Med; 2008 May 06;6:23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors.
  • The heterogeneity that soft tissue sarcomas (STS) exhibit in their clinical behavior, even within histological subtypes, complicates patient care.
  • Morphologic features are generally good predictors of biologic behavior, however, metastatic propensity, tumor growth, and response to chemotherapy may be determined by gene expression patterns that do not correlate well with morphology.
  • In this study, gene expression in 53 samples of STS and AF [including 16 malignant fibrous histiocytoma (MFH), 9 leiomyosarcoma, 12 liposarcoma, 4 synovial sarcoma, and 12 samples of AF] was determined at Gene Logic Inc. (Gaithersburg, MD) using Affymetrix GeneChip U_133 arrays containing approximately 40,000 genes/ESTs.
  • In addition, several genes that are targets of some anti-tumor drugs were found to be differentially expressed in particular subsets of STS.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1984 Feb 1;53(3):530-41 [6692258.001]
  • [Cites] J Lab Clin Med. 2004 Aug;144(2):78-91 [15322502.001]
  • [Cites] Cancer. 1986 Jul 15;58(2):306-9 [3719523.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):817-23 [3338039.001]
  • [Cites] Cancer. 1988 Sep 1;62(5):994-8 [3409180.001]
  • [Cites] Am J Physiol. 1992 Dec;263(6 Pt 1):L627-33 [1476204.001]
  • [Cites] Ann N Y Acad Sci. 1992 Dec 4;667:101-11 [1309029.001]
  • [Cites] Mod Pathol. 1995 Sep;8(7):705-10 [8539226.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Am J Pathol. 1997 Aug;151(2):329-34 [9250146.001]
  • [Cites] J Surg Oncol. 1999 Oct;72(2):77-82 [10518103.001]
  • [Cites] Cancer Immun. 2005 Feb 1;5:2 [15683221.001]
  • [Cites] Cancer Invest. 2005;23(2):105-18 [15813502.001]
  • [Cites] N Engl J Med. 2005 Aug 18;353(7):701-11 [16107623.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Histopathology. 2006 Jan;48(1):22-31 [16359534.001]
  • [Cites] Histopathology. 2006 Jan;48(1):51-62 [16359537.001]
  • [Cites] J Clin Oncol. 2006 Mar 1;24(7):1195-203 [16505440.001]
  • [Cites] J Lab Clin Med. 2006 May;147(5):250-67 [16697773.001]
  • [Cites] Transl Res. 2006 Nov;148(5):223-48 [17145569.001]
  • [Cites] J Natl Compr Canc Netw. 2007 Apr;5(4):364-99 [17442230.001]
  • [Cites] Mayo Clin Proc. 2007 Nov;82(11):1409-32 [17976362.001]
  • [Cites] Annu Rev Pathol. 2006;1:119-50 [18039110.001]
  • [Cites] Cancer Cell. 2007 Dec;12(6):514-27 [18068629.001]
  • [Cites] Oncogene. 1999 Nov 11;18(47):6615-20 [10597266.001]
  • [Cites] J Clin Pathol. 1999 Sep;52(9):695-6 [10655994.001]
  • [Cites] Nature. 2000 Feb 3;403(6769):503-11 [10676951.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] Int J Cancer. 2001 Mar 20;95(2):102-7 [11241320.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] Breast Cancer Res. 2001;3(6):365-72 [11737887.001]
  • [Cites] Lab Invest. 2002 Jan;82(1):97-103 [11796830.001]
  • [Cites] Hum Pathol. 2002 Jan;33(1):39-46 [11823972.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6973-8 [11983872.001]
  • [Cites] J Lab Clin Med. 2003 May;141(5):297-308 [12761473.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):1941-56 [12796356.001]
  • [Cites] Am J Pathol. 2003 Aug;163(2):691-700 [12875988.001]
  • [Cites] Cancer. 2003 Sep 1;98(5):1029-38 [12942572.001]
  • [Cites] J Lab Clin Med. 2004 Feb;143(2):89-98 [14966464.001]
  • [Cites] Clin Cancer Res. 2004 Jul 15;10(14):4776-83 [15269152.001]
  • [Cites] Cancer Immun. 2004 Aug 9;4:7 [15298487.001]
  • [Cites] J Clin Invest. 1985 Jan;75(1):11-8 [3965498.001]
  • (PMID = 18460215.001).
  • [ISSN] 1479-5876
  • [Journal-full-title] Journal of translational medicine
  • [ISO-abbreviation] J Transl Med
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA106878-03; United States / NCI NIH HHS / CA / R01 CA106878; United States / NCI NIH HHS / CA / R01 CA106878-03; United States / NCI NIH HHS / CA / R01CA106878
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Neoplasm
  • [Other-IDs] NLM/ PMC2412854
  •  go-up   go-down


28. Peyrí Rey E, Urban Ramón A, Martínez Fernández M, Sanmarti Da Silva B: [Dedifferentiated liposarcoma of spermatic cord: degeneration of lipoma previously resected]. Actas Urol Esp; 2003 May;27(5):383-6
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Dedifferentiated liposarcoma of spermatic cord: degeneration of lipoma previously resected].
  • [Transliterated title] Liposarcoma dediferenciado del cordón espermático: degeneración de un lipoma previo resecado.
  • Dedifferentiated liposarcoma accounts for only 10% of all spermatic cord sarcomas.
  • These are usually large-sized tumours histologically characterised for being well-differentiated liposarcomas with some high grade sarcoma areas.
  • Volume, location, mass homogeneity as well as presence of pelvic and retroperitoneal adenopathies are reported by CT and ultrasound techniques.
  • These are useful for post-treatment follow-up.
  • This paper presents one spermatic cord, dedifferentiated liposarcoma from which lipomas from the same spermatic cord had been previously removed in three occasions.
  • Value of adjuvant radio- and chemotherapy is uncertain.
  • [MeSH-major] Genital Neoplasms, Male / pathology. Lipoma / pathology. Liposarcoma / pathology. Spermatic Cord / pathology
  • [MeSH-minor] Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12891917.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas espanolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


29. Blom E, Heyning FH, Kroes WG: A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1). Cancer Genet Cytogenet; 2010 Oct 1;202(1):38-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of angioimmunoblastic T-cell non-Hodgkin lymphoma with a neocentric inv dup(1).
  • Acquired neocentromeres have been described in a particular class of lipomatous tumors (atypical lipomas and well-differentiated liposarcomas; ALP-WDLPS), three cases of acute myeloid leukemia (AML), one case of non-Hodgkin lymphoma (NHL), and one case of lung carcinoma.
  • It represented an inverted duplication of the segments between 1q21 and 1qter with a neocentromere in band 1q31.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chromosome Inversion. Chromosomes, Human, Pair 1. Gene Duplication. Immunoblastic Lymphadenopathy / genetics. Lymphoma, T-Cell / genetics
  • [MeSH-minor] Aged. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Humans. In Situ Hybridization, Fluorescence. Karyotyping. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / pathology. Male. Neoplasms, Second Primary. Prednisone / administration & dosage. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20804919.001).
  • [ISSN] 1873-4456
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


30. Rüsseler AV, Brors B, Fischer T, Hartmann JT, Hartmann W, Hohenberger P, Lichter P, Marx A, Mechtersheimer G, Penzel R, Renner M, Schildhaus HU, Schirmacher P, Sievers E, Ströbel P, Wardelmann E, Ziesché E, Büttner R: [Molecular pathology of sarcomas. Update on the research group "Molecular Diagnosis of Sarcomas"]. Pathologe; 2010 Oct;31 Suppl 2:211-4
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular pathology of sarcomas. Update on the research group "Molecular Diagnosis of Sarcomas"].
  • [Transliterated title] Molekularpathologie von Sarkomen. Erste Ergebnisse des Sarkomforschungsverbundes KoSar.
  • To establish precise diagnostic algorithms and standardised treatment of sarcomas in specialized centers, the interdisciplinary research group KoSar (sarcoma competence network) has been funded by German Cancer Aid.
  • A sarcoma tissue repository and a diagnostic reference center have been set up, presently containing about 1000 accurately diagnosed sarcomas of different entities.
  • Significant gene expression profiles for synovial sarcomas, leiomyosarcomas, myxoid liposarcomas and a small profile for myxofibrosarcomas as well as a new classification of angiosarcomas were defined.
  • We systematically searched for activated signal transduction pathways in sarcoma cell lines and xenograft transplant models and candidate targets for molecular therapies were identified.
  • [MeSH-minor] Animals. Biomedical Research. Cell Line, Tumor. Cooperative Behavior. Drug Evaluation, Preclinical. Fibrosarcoma / diagnosis. Fibrosarcoma / drug therapy. Fibrosarcoma / genetics. Fibrosarcoma / pathology. Gene Expression Profiling. Gene Expression Regulation, Neoplastic / genetics. Humans. Interdisciplinary Communication. Leiomyosarcoma / diagnosis. Leiomyosarcoma / drug therapy. Leiomyosarcoma / genetics. Leiomyosarcoma / pathology. Liposarcoma, Myxoid / diagnosis. Liposarcoma, Myxoid / drug therapy. Liposarcoma, Myxoid / genetics. Liposarcoma, Myxoid / pathology. Molecular Diagnostic Techniques. Molecular Targeted Therapy. Neoplasm Transplantation. Sarcoma, Synovial / diagnosis. Sarcoma, Synovial / drug therapy. Sarcoma, Synovial / genetics. Sarcoma, Synovial / pathology. Signal Transduction / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pathol. 2008 Dec;216(4):428-39 [18855347.001]
  • [Cites] Virchows Arch. 2010 Mar;456(3):277-85 [20039060.001]
  • [Cites] J Pathol. 2008 Oct;216(2):176-82 [18686281.001]
  • [Cites] Am J Pathol. 2010 Jan;176(1):34-9 [20008140.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4550-5 [18628470.001]
  • (PMID = 20711583.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


31. Montgomery E, Fisher C: Paratesticular liposarcoma: a clinicopathologic study. Am J Surg Pathol; 2003 Jan;27(1):40-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paratesticular liposarcoma: a clinicopathologic study.
  • Paratesticular liposarcomas are rare and typically reported as isolated cases or as components of larger studies of liposarcomas.
  • All cases of paratesticular liposarcomas were retrieved from the archives of the Royal Marsden Hospital and the Johns Hopkins Hospital.
  • There were 30 paratesticular liposarcomas from men aged 41-87 years (mean 63 years; median 65 years) that involved the spermatic cord (23, 76%), testicular tunics (6, 20%), and epididymis (1, 4%).
  • Nineteen were well-differentiated liposarcomas (WDLs) and 10 were dedifferentiated liposarcomas (DDLs, five with high-grade and five with low-grade dedifferentiation).
  • One was a myxoid/round cell liposarcoma with 70% round cell areas.
  • One patient with WDL received radiation after his second recurrence and the myxoid/round cell liposarcoma received radiation and chemotherapy.
  • Follow-up information was available for 16 of the patients, including 10 WDLs (range 24-216 months, mean 106 months), 5 DDLs (14-30 months, median 24 months), and for the myxoid/round cell liposarcoma (14 months) (range for all cases 14 months to 22 years; mean 87 months, median 36 months).
  • Six of the WDLs (60%) recurred at 2, 4, 6, 10, 18, and 21 years (median 8 years).
  • One patient with WDL had two recurrences at 4 and 7 years, and another had six recurrences over a 17-year period.
  • Only one example of DDL recurred, at 30 months; another patient, who refused therapy for 15 years, had a primary tumor 30 cm in diameter, displayed pulmonary metastases 1 month after excision, and died after 14 months.
  • In summary, paratesticular WDL had a prolonged course with recurrences in more than half the cases, sometimes late.
  • One DDL recurred and only one of five (20%) developed metastases, but the mean follow-up for DDL was only 24 months.
  • [MeSH-major] Liposarcoma / secondary. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12502926.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement